Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy

[1]  Timothy A. Miller,et al.  Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2020, The New England journal of medicine.

[2]  J. Rempel,et al.  Pro-Inflammatory Signaling Upregulates a Neurotoxic Conotoxin-Like Protein Encrypted Within Human Endogenous Retrovirus-K , 2020, Cells.

[3]  P. Vourc'h,et al.  Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis , 2020, International journal of molecular sciences.

[4]  A. Al-Chalabi,et al.  Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[5]  A. Nath,et al.  Technical considerations in detection of HERV-K in amyotrophic lateral sclerosis: selection of controls and the perils of qPCR , 2019, Acta neuropathologica communications.

[6]  A. Al-Chalabi,et al.  Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis , 2019, Acta neuropathologica communications.

[7]  Timothy A. Miller,et al.  Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia , 2019, bioRxiv.

[8]  A. Nath,et al.  Human endogenous retrovirus-K (HML-2): a comprehensive review , 2018, Critical reviews in microbiology.

[9]  E. Meese,et al.  Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins , 2018, Molecular Neurodegeneration.

[10]  L. Sechi,et al.  Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases , 2018, European journal of neurology.

[11]  D. Markovitz,et al.  Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors , 2017, Journal of Virology.

[12]  A. Nath,et al.  Inhibition of human endogenous retrovirus-K by antiretroviral drugs , 2017, Retrovirology.

[13]  Bryan R. Smith,et al.  HIV-associated motor neuron disease , 2016, Neurology.

[14]  L. Larocque,et al.  Further Evidence that Human Endogenous Retrovirus K102 is a Replication Competent Foamy Virus that may Antagonize HIV-1 Replication , 2015, The open AIDS journal.

[15]  Dragan Maric,et al.  Human endogenous retrovirus-K contributes to motor neuron disease , 2015, Science Translational Medicine.

[16]  O. Hardiman,et al.  A revision of the El Escorial criteria - 2015 , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[17]  Marta J. Gonzalez-Hernandez,et al.  Genomic flexibility of human endogenous retrovirus type K , 2013, Journal of Virology.

[18]  M. Garcia-Montojo,et al.  MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up , 2012, BMC Neurology.

[19]  J. Rothstein,et al.  Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis , 2011, Annals of neurology.

[20]  A. Al-Chalabi,et al.  Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate , 2008, Neurology.

[21]  L. Larocque,et al.  The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia , 2007, AIDS.

[22]  B. Polsky,et al.  A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS , 2007, Neurology.

[23]  S. Weiss,et al.  Effects of Type I Interferons on Friend Retrovirus Infection , 2006, Journal of Virology.

[24]  R. Ellis,et al.  Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid , 2005, Antimicrobial Agents and Chemotherapy.

[25]  H. Mitsumoto,et al.  A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS , 2005, Neurology.

[26]  A. Al-Chalabi,et al.  Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives , 2005, Neurology.

[27]  S. A. Thomas,et al.  Effect of Transport Inhibitors and Additional Anti-HIV Drugs on the Movement of Lamivudine (3TC) across the Guinea Pig Brain Barriers , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  A. Al-Chalabi,et al.  Detection of reverse transcriptase activity in the serum of patients with motor neurone disease , 2000, Journal of medical virology.

[29]  E. Beghi,et al.  A randomized controlled trial of recombinant interferon beta-1a in ALS , 2000, Neurology.

[30]  H. Kornhuber,et al.  Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. , 1993, Neuroreport.

[31]  S. Spiegelman,et al.  RNA-instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients , 1975, The Journal of experimental medicine.

[32]  M. Garcia-Montojo,et al.  Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients , 2011, Journal of Neurovirology.

[33]  E. Beghi,et al.  A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group. , 2000, Neurology.